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Introduction
Small molecule drugs and therapeutic proteins are frequently co-administered to patients with cancer or immune-mediated inflammatory disease such as rheumatoid arthritis. Although the absorption, distribution, metabolism and excretion properties of small molecule drugs and therapeutic proteins (also known as biologic drugs) are distinct, the two classes of drugs can alter each other's disposition and therefore have the potential for drug-drug interactions (DDI) (Evers et al., 2013) . Changes in the clearance of small molecule drugs caused by certain therapeutic proteins can be a consequence of the suppression of drug-metabolizing enzymes (DME) or transporters Lee et al., 2010; Zhou and Mascelli, 2011) . The decrease in victim drug clearance, and consequently increase in drug exposure, can lead to toxicity, loss of efficacy or exaggerated pharmacological effects, as shown with cyclosporine, tacrolimus, and simvastatin (Vasquez and Pollak, 1997; Strehlau et al., 2000; Sifontis et al., 2002; Schmitt et al., 2011) . Suppression of DME and transporters by certain biologic drugs involves a release of cytokines from the peripheral blood mononuclear cells (PBMC), followed by activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and down-regulation of aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) and pregnane X receptor (PXR) (Ke et al., 2001; Morgan et al., 2002; Riddick et al., 2004; Morgan, 2009) . Additionally, Kupffer cells can release cytokines such as TNF-α and IL-6 which modulate suppression of CYP3A4 in hepatocytes in vitro (Hoebe et al., 2001; Sunman et al., 2004) . Therapeutic proteins that are cytokines or cytokine modulators can suppress DME by acting directly on hepatocytes (Ghose et al., 2011) and/or Kupffer cells, as has been shown for INFα-2B with theophylline and methadone clearance (Iafolla, 2002) ; whereas other therapeutic proteins, such as OKT3 antibody, cause systemic reaction by stimulating cytokine release from PBMC (Abramowicz et al., 1989; Chatenoud et al., 1990; Herbelin et al., 1999; Wolf et al., 2012) . The effects of therapeutic proteins that directly suppress drug metabolism can be examined in a traditional hepatocyte culture (Kraynov et al., 2011) . In contrast, for those This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 17, 2014 as DOI: 10.1124 at ASPET Journals on June 24, 2017 dmd.aspetjournals.org Downloaded from DMD #060186 therapeutic proteins that stimulate a cytokine response in blood, a traditional hepatocyte culture treated with the drug alone may be an inadequate test system to assess DDI potential (Dallas et al., 2012; Evers et al., 2013) .
The in vitro effects of numerous pro-inflammatory cytokines on CYP enzymes have been demonstrated (Aitken and Morgan, 2007; Dickmann et al., 2011; Dallas et al., 2013) . However, such studies usually examine the effects of only a single, or a limited combination of cytokines (Dickmann et al., 2012b) . It has been noted that many cytokines cross-regulate their own expression and that cytokines can suppress or induce CYP expression in vitro (Marie et al., 1996; Liptrott et al., 2009; Barker et al., 2011; Dickmann et al., 2012a) . Despite the understanding that cytokines act as a network of signaling molecules, the effects of a full complement of cytokine response to a therapeutic protein on DME have not been studied in
vitro.
The 2012 FDA Draft Guidance for Industry on drug interaction specified that studies for the prediction of therapeutic protein-small molecule drug DDI may be performed in vitro (Food and Drug Administration (US) and (CDER), 2012). In the present study, we propose a novel method that comprises stimulation of whole human blood with a therapeutic protein, followed by separation and subsequent incubation of the plasma with human hepatocytes co-cultured with Kupffer cells to assess the potential of the therapeutic protein to alter the disposition of small molecule drugs. All cultures of hepatocytes used in this study were in fact co-cultures of hepatocytes and Kupffer cells isolated from the same donors in routine perfusion and plating procedures. The test system accounts for cumulative effects of all cytokines stimulated by therapeutic protein in blood on CYP expression. We selected LPS and ANC28.1, a monoclonal antibody against T-cell receptor CD28, to demonstrate proof of concept for the new method (Fig. 1 ). Our choice of ANC28.1 was based on another anti-CD28 antibody, TGN1412, which This article has not been copyedited and formatted. The final version may differ from this version. 6 caused cytokine storm and severe toxicity in a first-in man study and dramatically highlighted the need to improve preclinical safety assessment of therapeutic proteins (Suntharalingam et al., 2006) . We stimulated release of cytokines in whole human blood with LPS and ACN28.1, quantified the cytokines in plasma and examined their effects on CYP mRNA levels and enzyme activities in human hepatocytes co-cultured with Kupffer cells. This study demonstrates the feasibility of an in vitro DDI evaluation of therapeutic proteins that stimulate cytokine release in blood.
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Materials and Methods
Chemicals and reagents. ANC28.1, a mouse monoclonal antibody against human T-cell receptor CD28 (anti-CD28) and MOPC 31C, a control mouse monoclonal antibody (of unknown antigen specificity) with the same subtype as ANC28.1, namely IgG1-κ, were purchased from Ancell Corp. (Bayport, MN) and diluted with purified saline. E.coli LPS was purchased from Sigma-Aldrich (St. Louis, MO). Endotoxin Removal Gel was purchased from Pierce Biotechnology (Rockford, IL). Blood was donated by healthy volunteers who gave informed consent to participate in the study. Interleukin 6 (IL-6) and TRIzol were purchased from EMD Biosciences (La Jolla, CA) and Invitrogen (Grand Island, NY), respectively. The sources of the other reagents used in this study have been described elsewhere (Paris et al., 2009 ).
Cytokine release assay. Normal sterile saline was purified with Endotoxin Removal Gel as described by Pierce Biotechnology (Rockford, IL). A stock solution of LPS (5 µg/mL) was prepared in purified saline. Blood was drawn into sterile glass 10 mL vacutainers containing sodium heparin (product # 8362834, Becton-Dickinson, Franklin Lakes, NJ), transferred into sterile 50 mL polypropylene tubes (BD Biosciences, San Diego, CA) and aliquoted into sterile polypropylene micro tubes (Sarstedt, Newton, NC). Saline (2%, v/v), LPS (50 ng/mL) or the antibodies (2 μ g/mL) were added to blood in an aqueous solution, gently mixed and incubated at 37°C for 24 h. Plasma was separated from whole blood by centrifugation at 600 x g for 10 min, aliquoted and stored at -80°C. Interferon-γ (IFN-γ), interleukin (IL)-1β , IL-2, IL-6,IL-8, IL-10, IL-12p70, tumor necrosis factor-α (TNF-α), and granulocyte monocyte-colony stimulating factor (GM-CSF) were measured in the plasma by sandwich immunoassay with electrochemiluminescence detection with a Human Proinflammatory 9-Plex Ultra-Sensitive Kit (catalog # K15007C-1, Meso Scale Discovery, Gaithersburg, MD) according to the manufacturer's instructions. The measurements were conducted by Viracor-IBT Laboratories (Lee's Summit, MO) with a SECTOR® Imager 2400 (Meso Scale Discovery, Gaithersburg, MD).
This article has not been copyedited and formatted. The final version may differ from this version. Kupffer cells were isolated by a two-step collagenase perfusion method and plated on collagencoated 24-well plates, as described previously (Madan et al., 2003) . This isolation and plating procedure routinely resulted in a co-culture of hepatocytes and liver macrophages (Lambert Li et al., 2013) . Kupffer cells were stained with anti-CD68 antibody followed by Alexa Fluor ® 488-conjugated secondary antibody and fluorescent microscopy ( Supplementary Fig. 1 ), and comprised ~ 4.7% of the plated cells, although in vivo macrophages may be present at a higher proportion (4 -8%) (Racanelli and Rehermann, 2006) . Cells were treated according to published protocols (Robertson et al., 2000; Paris et al., 2009 Table 1 . The concentration of ANC28.1 was based on a 0.1 mg/kg dose of TGN1412 given to human volunteers (Stebbings et al., 2007) . In general, the levels of cytokines in plasma from blood treated with saline for 24 h were consistent with endogenous levels reported by the assay's manufacturer Table 2 . Because different sets of cell cultures were used in the LPS and ANC28.1 experiments, they are presented separately. Hepatocytes treated with cell culture medium (MCM+) with no plasma served as control. The concentration of marker substrate metabolites formed in the control cultures was used to normalize results from the cultures treated with IL-6, LPS or ANC28.1. IL-6 caused suppression of CYP1A2 and CYP2B6 mRNA to 28% and 24% of control, respectively. The greatest effect of IL-6 was suppression of CYP3A4 mRNA to less than 1% of control. Treatment of human hepatocytes with IL-6 decreased CYP1A2, CYP26 and CYP3A4 enzyme activity to 30%, 24% and 17% of control, respectively. In human hepatocytes suppression of CYP mRNA levels and enzyme activity by LPS was comparable to that of the IL-6 treatment. LPS suppressed CYP1A2, CYP2B6 and CYP3A4 mRNA to 62%, 44% and 2% of control, respectively. As expected, LPS reduced enzyme activity of CYP1A2, CYP2B6 and CYP3A4 to 46%, 90% and 29% of control, respectively. In contrast to IL-6 and LPS, the ANC28.1 antibody had little or no effect on CYP mRNA levels or enzyme activity.
Effects of plasma from saline-or MOPC 31C-treated blood on CYP enzymes in human hepatocytes in vitro. The effects of plasma (0 -50%, v/v) from saline-or MOPC 31C-treated blood (saline plasma or MOPC 31C plasma) on CYP mRNA expression and enzyme activity in human hepatocytes after 72 h are shown in Fig. 3 and Supplemental Table 3 . Cells treated with medium (MCM+) with no plasma served as control. Saline plasma and MOPC 31C plasma both demonstrated a concentration-dependent trend toward suppression of CYP1A2 mRNA levels (to about 60% of control at 50% plasma) (Fig. 3A) . Saline plasma caused an even greater suppression of CYP3A4 mRNA levels (to about 2% of control at 50% plasma) (Fig. 3B) . MOPC 31C plasma also demonstrated a trend toward suppression of CYP3A4 mRNA levels but to a lesser extent than saline plasma (to about 33% of control at 50% plasma) (Fig. 3B) . Large culture-to-culture variation in plasma-mediated suppression was observed, as evident from the large standard deviations associated with data for all three CYP mRNA transcripts. In contrast to the effects on CYP1A2 and CYP3A4, saline plasma and MOPC 31C plasma both induced CYP2B6 mRNA levels about two fold (Fig. 3C) . Treatment of human hepatocytes with saline plasma or MOPC 31C plasma had little or no effect on CYP1A2 activity with the exception of the highest concentration of saline plasma (50% v/v in media), which reduced enzyme activity of CYP1A2 to 65% of control (Fig. 3D) . Treatment of human hepatocytes with saline plasma or MOPC 31C plasma decreased CYP3A4 enzyme activity to 52% and 76% of control, respectively (Fig. 3E) . Saline plasma and MOPC 31C plasma both induced CYP2B6 activity about three fold (Fig. 3F ). Large standard deviations were associated with data for all three CYP activities. The mechanism underlying the difference between the two control plasma samples was not investigated, although the levels of many of the cytokines in saline plasma were 2 to 4 fold higher than those in MOPC 31C plasma ( Table 1) .
Effects of plasma from LPS-treated blood treated on CYP enzymes in human
hepatocytes. Plasma from LPS-treated blood was applied to hepatocytes (3 donors) to assess the whole blood-mediated effects of endotoxin on CYP enzymes. As a positive control for CYP suppression, hepatocytes were treated with IL-6 at 10 ng/mL, which was comparable to the concentration of IL-6 in LPS plasma (Table 1) . Cultures treated with medium only or 10%, 20%
or 50% (v/v) saline plasma served as controls. The data are presented in Fig. 4 and Supplemental Table 3 . Treatment of human hepatocytes with the LPS plasma revealed the cytokine-mediated effect of endotoxin. The LPS plasma suppressed CYP1A2 mRNA to 2% and CYP1A2 activity to 29% of control (observed with 50% v/v plasma, Fig. 4A ), suppressed CYP2B6 mRNA to 12% and CYP2B6 activity to 11%of control (observed with 50% v/v plasma) and suppressed CYP3A4 mRNA to 1% and CYP3A4 activity to 31% of control (observed with 10% of plasma in medium). Increasing the concentration of LPS plasma from 10% to 50% did not increase the extent to which CYP1A2 activity was suppressed (Supplemental Table 3 ) and actually decreased (not increased) the extent to which CYP3A4 activity was reduced (Fig.4, Supplemental Table 3 ). The reduction in CYP1A2 enzyme activity caused by direct application of LPS (to 46% of control) ( Table 3 ). The reduction in CYP3A4 enzyme activity caused by direct application of LPS (to 29% of control) was also similar to that caused by 10%
LPS plasma (31% of control) and greater than that caused by 50% LPS plasma (54% of control) (Tables 2, Fig 4, Supplemental Table 3 ).
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Plasma from ANC28.1-treated blood (ANC28.1 plasma) was applied to hepatocytes (3 donors) to assess the whole blood-mediated effects of ANC28.1 on CYP enzyme expression. Cultures treated with IL-6 served as positive control for CYP suppression (Table 2 ). Cultures treated with MCM+ or MOPC 31C plasma served as controls. The data are presented in Fig. 5 and Supplemental Table 3 . The effects of the ANC28.1 plasma on CYP expression were normalized to MOPC.31C plasma. In contrast to the effects of LPS, the direct addition of ANC28.1 to hepatocytes had little or no effect on CYP1A2, CYP2B6 and CYP3A4 mRNA levels or enzyme activity, although in some cases standard deviations associated with the data were approaching 40 or 50% of the mean (Table 2 and Fig. 5 ). This observation is in agreement with expression of CD28 being restricted to T cells (Su et al., 2004) . In contrast, treatment of human hepatocytes with plasma from ANC28.1-treated blood revealed the suppressive effect of cytokines released from ANC28.1-stimulated PBMCs. Compared with the control (MOPC 31C) plasma, ANC28.1 plasma suppressed CYP1A2 mRNA and enzyme activity to 31% and 51% of control, respectively, suppressed CYP2B6 mRNA and activity to 42% and 32% of control, respectively, and suppressed CYP3A4 mRNA and activity to 11% and 40% of control, respectively (Fig. 5 , Supplemental Table 3 ). In most cases, a trend toward concentrationdependent suppression was observed. Error bars associated with the data in Fig. 5 indicated that the suppression of CYP was associated with significant inter-individual variability.
Discussion
The suppression of CYP enzymes and other DME by certain therapeutic proteins and the rise in the co-administration of therapeutic proteins with small molecule drugs create the potential for clinical DDIs. We investigated a new in vitro method for evaluating therapeutic proteins as perpetrators of DDIs with small molecule drugs (Fig. 1) . The method consists of adding the therapeutic protein to human blood ex vivo to permit the release of cytokines from PBMCs followed by the preparation of plasma and an assessment of its effects on DME in human hepatocytes co-cultured with Kupffer cells. Suppression of DME by certain therapeutic proteins commonly involves the release of cytokines from PBMCs (Morgan et al., 2002; Morgan et al., 2008) . Current procedures to assess therapeutic proteins as perpetrators of DDIs rely primarily on clinical studies because the predictive value of applying cytokines individually or in a limited combination to hepatocytes in vitro is not well established (Girish et al., 2011; Evers et al., 2013) . However, the current in vitro approach may be inadequate because a cytokine response comprises multiple inductive and suppressive molecules (Marie et al., 1996; Liptrott et al., 2009; Barker et al., 2011; Dickmann et al., 2012b) . The complexity of the regulation of DME is exemplified by studies of interferon-α2B. This cytokine down-regulated the mRNA encoding CYP1A2, CYP2B6, CYP2E1, UDP-glucuronosyltransferase UGT2B7, sulfotransferase SULT1A1, and the organic anion transporter OAT2, but it up-regulated the mRNA encoding CYP3A4 and multidrug resistance-associated protein 2 (MRP2) in co-cultures (parenchymal and non-parenchymal cells) of human hepatocytes in vitro (Chen et al., 2011) . Similarly, IL-1β and IL-6, when applied individually, suppressed P450 enzymes, but when co-administered with TNFα these two interleukins induced several P450 enzymes in mouse hepatocytes (Dickmann et al., 2012a) . In light of these observations we propose that the full complement of therapeutic protein-stimulated cytokines should be applied to human hepatocytes to assess the potential for
DDI.
This article has not been copyedited and formatted. The final version may differ from this version. When added to whole human blood ex vivo, LPS and ANC28.1 both increased the plasma levels of IFN-γ, IL-1β, IL-2, IL-6 and TNF-α in agreement with published reports with monoclonal antibody TGN1412, which is also directed against CD28 (Shedlofsky et al., 1994; Suntharalingam et al., 2006; Wolf et al., 2012) . Signaling by LPS is mediated by binding to the CD14/TLR4/MD2 receptor complex that is expressed by hepatocytes, Kupffer cells and stellate cells in the liver, as well as extra-hepaticlly in monocytes, intestine, heart and multiple other organs (Shimazu et al., 1999; Paik et al., 2003; Scott and Billiar, 2008) . In a study in six healthy subjects, LPS stimulated release of circulating TNF and IL-6 followed by a reduction in clearance of the CYP substrate antipyrine, the extent of which correlated with peak levels of plasma cytokines in six healthy subjects (Shedlofsky et al., 1994) . Wolf and coauthors (2012) added ANC28.1 to whole human blood in aqueous solution for 24 h and observed increases in IFN-γ, IL-2, IL-6, IL-8, IL-10 and TNF-α that matched our results. In a first-in-man study, the anti-CD28 antibody TGN1412 caused marked increases (up to 5,000 fold) in INF-γ, IL-1ß, IL-2, IL-6, IL-8, and TNF-α in six humans (Suntharalingam et al., 2006) . In our study ANC28.1, added to human blood ex vivo, increased the plasma levels of the same proinflammatory cytokines although to a lesser extent than TGN1412 in vivo. Addition of ANC28.1 or TGN1412
to isolated human T-cells stimulated the release of high levels of the pro-inflammatory cytokines INF-γ, TNF-α, IL-2, IL-5, and the anti-inflammatory cytokines IL-4 and, to a lesser extent, IL-10 (Waibler et al., 2008) . In our study, the 93-fold increase in IL-2 in whole blood ex vivo was one of the qualitative differences in the cytokine response to ANC28.1 compared with LPS ( Table 1 ).
The temporal effects of 10% LPS plasma or saline plasma on CYP1A2 and CYP2B6 mRNAs were comparable in hepatocytes from six livers at 72 h (Fig. 2 , Supplemental Table 3 ). In contrast, 10% saline plasma reduced CYP3A4 mRNA at 72 h in one set of hepatocytes cultures but increased in the other set (Fig. 2 , Supplemental Table 3 ). This discrepancy can be attributed to interindividual variability in the response of co-cultured hepatocytes to cytokines. to LPS plasma. In contrast to its effects on CYP1A2 and CYP3A4, the effects of LPS plasma on CYP2B6 were without a clear time dependency.
The effects of the cytokines released from the whole blood treated with LPS on CYP mRNA levels varied between the enzymes, indicating gene-specific mechanisms of suppression and cautioning against extrapolating individual results to multiple DMEs. Aitken and Morgan (2007) observed down-regulation of multiple human CYP mRNAs and proteins by LPS, as well as recombinant IL-6, following 24-h treatment of hepatocytes. These investigators observed variable and suppressor-specific effects on CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19
and CYP3A4 mRNA levels. Suppression of CYP3A4 mRNA in response to treating freshly plated hepatocytes with LPS, which was comparable to our results obtained with LPS plasma, was observed in one of two cultures studied by Aitken and Morgan, although the cultures were not analyzed for the presence of Kupffer cells. Suppression of CYP2B6 in response to treatment of hepatocytes with LPS (10 μ g/mL) was not observed (Aitken and Morgan, 2007) . In general, results of the two studies indicated the importance of gene-and hepatocyte culturespecific factors for CYP enzyme suppression in vitro.
In our method, the therapeutic protein-stimulated cytokines are applied to the hepatocytes in plasma; consequently, we normalized the effects of LPS plasma and ANC28.1 plasma to saline plasma and MOPC 31C plasma, respectively. This design isolates the effects of the therapeutic protein-stimulated cytokines from the effects of other components of human plasma. In our study, proteins present in saline plasma (50% plasma in medium) significantly suppressed CYP1A2 and had a pronounced suppressive effect on CYP3A4 mRNA. In contrast to these suppressive effects, saline plasma actually induced CYP2B6 mRNA levels (Fig. 3, Supplemental Table 3 ). These effects were, in general, dependent on the concentration of plasma in the cell culture medium (most pronounced in cultures exposed to 20 or 50% of enzymes or CYP2D6 (Takeba et al., 2011) . In our study, although the two control plasma samples had similar effects on CYP1A2, their effects on CYP3A4 mRNA differed (Fig. 3 ). The saline plasma had a greater suppressive effect on CYP3A4 mRNA than MOPC 31C plasma.
The saline plasma contained more IL-10 (and other cytokines) than MOPC 31C plasma. It remains to be explored whether IL-10 contributed to suppression of CYP3A4 mRNA. The inductive effect of both control plasmas on CYP2B6 is a novel observation. For all three genes the effects of the control plasma on CYP mRNA levels were more pronounced than their effects on CYP activity. This finding might reflect differences between mRNA and protein degradation rates. In general, changes in CYP mRNA levels and enzyme activities were in good agreement.
When added directly to hepatocyte co-cultures, LPS directly suppressed CYP1A2, CYP2B6 and CYP3A4 mRNA levels and enzyme activity of CYP1A2 and CYP3A4 (Table 2 , Fig. 4 ). The suppressive effects were greater on CYP3A4 than CYP1A2, as previously observed in freshly plated hepatocytes (Aitken and Morgan, 2007 plasma indicated that, in general, the cytokines augmented the effects of the endotoxin (Table   1 ). In contrast to LPS, ANC28.1 antibody had little or no direct effect on CYP1A2, CYP2B6 and CYP3A4 mRNA levels or enzyme activity (Table 2 , Fig. 4 ). This negative effect contrasts with the suppression of CYP1A2 and CYP3A4 observed with AGN28.1 plasma. We attribute this effect to the cytokines released from ANC28.1-stimulated whole blood. In general, the ANC28.1 plasma contained less cytokines than LPS plasma (with the notable exception of IL-2), which correlated with less mRNA suppression ( Table 1 , Fig. 4 ).
In the present study we established proof of concept for the new in vitro method to identify therapeutic proteins that can suppress hepatic DMEs by stimulating the release of cytokines in whole blood. We demonstrated that, when added to whole human blood ex vivo, LPS and ANC28.1 antibody caused the release of multiple cytokines capable of suppressing the mRNA and the enzymatic activity of hepatic CYP1A2, CYP2B6 and CYP3A4 in vitro. Furthermore, we
showed that the DDI potential of certain therapeutic proteins, like ACN28.1, can be identified in vitro provided that cytokine release from whole blood is taken into account. The direct application of ANC28.1 to hepatocytes, which caused no suppression of CYP1A2, CYP2B6 or CYP3A4, would be interpreted as a lack of potential to affect DMEs in vivo -a false negative assessment. At the current stage of our investigation we believe that a method comprising ex vivo treatment of human blood followed by an evaluation of the effects of cytokine-containing plasma on DME expression in human hepatocyte co-cultures can expand the utility of in vitro methods to identify those therapeutic proteins with the potential to alter the disposition of small molecule drugs.
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